Opendata, web and dolomites

GOLIATH SIGNED

Beating Goliath: Generation Of NoveL, Integrated and Internationally Harmonised Approaches for Testing Metabolism Disrupting Compounds

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GOLIATH project word cloud

Explore the words cloud of the GOLIATH project. It provides you a very rough idea of what is the project "GOLIATH" about.

incorporating    urgent    health    disrupt    validated    disrupting    throughput    comprised    ready    entire    outcome    proportions    liver    pancreatic    silico    action    worldwide    induce    exposures    epidemiology    adverse    experts    chemical    omics    bhc    ultimately    molecular    first    27    natural    regulatory    hepatocytes    world    vitro    toxicity    diabetes    disruption    cells    endocrine    regulation    span    obesity    mode    metabolism    internationally    focussing    edcs    mdcs    cellular    screening    predictive    ongoing    collectively    life    sc1    optimise    aop    guidelines    adipocytes    harmonised    toxicology    chemicals    endocrinology    anthropogenic    myocytes    oecd    generate    international    metabolic    technologies    goliathan    assays    human    reached    acceptance    fatty    disorders    strategy    vivo    goliath    iata    humans    validation    reduce    link    spectrum    outcomes    pivotal    biology    2018    lack    translating   

Project "GOLIATH" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT UTRECHT 

Organization address
address: HEIDELBERGLAAN 8
city: UTRECHT
postcode: 3584 CS
website: www.uu.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 6˙761˙833 €
 EC max contribution 6˙761˙833 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT UTRECHT NL (UTRECHT) coordinator 1˙268˙269.00
2    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 1˙077˙695.00
3    INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT FR (PARIS CEDEX 07) participant 798˙786.00
4    UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE ES (ELCHE) participant 672˙862.00
5    Department of Health UK (Leeds) participant 459˙104.00
6    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 402˙500.00
7    THE REGENTS OF THE UNIVERSITY OF CALIFORNIA US (OAKLAND CA) participant 339˙596.00
8    LINKOPINGS UNIVERSITET SE (LINKOPING) participant 338˙287.00
9    UMEA UNIVERSITET SE (UMEA) participant 303˙750.00
10    BRUNEL UNIVERSITY LONDON UK (UXBRIDGE) participant 261˙946.00
11    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 248˙525.00
12    BIOPREDIC INTERNATIONAL SARL FR (SAINT GREGOIRE) participant 243˙750.00
13    VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK N.V. BE (MOL) participant 137˙510.00
14    AGENCE NATIONALE DE LA SECURITE SANITAIRE DE L ALIMENTATION DE L ENVIRONNEMENT ET DU TRAVAIL FR (MAISONS ALFORT) participant 134˙250.00
15    HOFFMANN SEBASTIAN DE (PADERBORN) participant 75˙000.00

Map

 Project objective

GOLIATH addresses the work programme topic ‘SC1-BHC-27-2018: New testing and screening methods to identify endocrine disrupting chemicals (EDCs)’ by focussing on one of the most urgent regulatory needs, namely the lack of methods for testing EDCs that disrupt metabolism – chemicals collectively referred to as ‘metabolism disrupting chemicals’ (MDCs). MDCs are natural and anthropogenic chemicals that have the ability to promote metabolic changes that can ultimately result in obesity, diabetes and/or fatty liver in humans. GOLIATH will generate the world’s first integrated approach to testing and assessment (IATA) specifically tailored to MDCs. With a focus on the main cellular targets of metabolic disruption – hepatocytes, pancreatic endocrine cells, myocytes and adipocytes - GOLIATH will develop new methods and optimise existing methods that span the entire adverse outcome pathway (AOP) spectrum, using in silico predictive modelling and high throughput screening, (pre-)validated ready-to-use in vitro assays and optimised in vivo toxicity testing guidelines. GOLIATH will provide key information on the endocrine mode of action by which MDCs disrupt metabolic pathways and induce adverse effects on human health by incorporating multi-omics technologies, and translating results from in vitro and in vivo assays to adverse metabolic health outcomes in humans at real life exposures. Given the importance of international acceptance of the developed test methods for regulatory use, GOLIATH will link with ongoing initiatives of the OECD for test method (pre-)validation, IATA and AOP development. With a consortium comprised of world-leading experts in endocrinology, molecular biology, toxicology, epidemiology, test method development, validation and chemical regulation, GOLIATH will be pivotal in the development of an internationally harmonised strategy for testing MDCs, and help to reduce the worldwide rise in metabolic disorders that have reached ‘Goliathan’ proportions.

 Deliverables

List of deliverables.
Detailed review paper on state of the art on MDCs Documents, reports 2020-03-06 13:48:50
Website open to the general public Websites, patent fillings, videos etc. 2020-02-25 14:36:32

Take a look to the deliverables list in detail:  detailed list of GOLIATH deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Melanie Schneider, Jean-Luc Pons, William Bourguet, Gilles Labesse
Towards accurate high-throughput ligand affinity prediction by exploiting structural ensembles, docking metrics and ligand similarity
published pages: 160-168, ISSN: 1367-4803, DOI: 10.1093/bioinformatics/btz538
Bioinformatics 36/1 2020-02-25
2019 Melanie Schneider, Jean-Luc Pons, Gilles Labesse, William Bourguet
In Silico Predictions of Endocrine Disruptors Properties
published pages: 2709-2716, ISSN: 1945-7170, DOI: 10.1210/en.2019-00382
Endocrinology 160/11 2020-02-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GOLIATH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GOLIATH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More  

DC-ren (2020)

Drug combinations for rewriting trajectories of renal pathologies in type II diabetes (DC-ren)

Read More  

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More